Xilio Therapeutics to Unveil Preclinical Data on CLDN18.2-Targeting T Cell Engager at AACR
Event summary
- Xilio Therapeutics will present preclinical data on XTX601, a masked Claudin 18.2-targeting T cell engager, at the AACR Annual Meeting on April 20, 2026.
- The poster presentation is scheduled for 9:00 a.m. to 12:00 p.m. PST in Poster Section 10, Board 11, with Abstract Number 1619.
- XTX601 is part of Xilio's masked immuno-oncology (I-O) therapies designed to selectively activate within the tumor microenvironment.
- Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated I-O molecules.
The big picture
Xilio Therapeutics' presentation at AACR highlights the growing focus on targeted immuno-oncology therapies that minimize systemic side effects. The company's masked T cell engager technology aims to address the limitations of current I-O treatments, aligning with broader industry trends towards more precise and effective cancer therapies. The success of XTX601 could position Xilio as a key player in the CLDN18.2-targeting space, potentially attracting further investment and partnerships.
What we're watching
- Clinical Validation
- The effectiveness of XTX601 in preclinical studies will determine its potential to advance to clinical trials.
- Competitive Positioning
- Xilio's ability to differentiate XTX601 from other CLDN18.2-targeting therapies will be crucial for market adoption.
- Partnership Leverage
- The impact of collaborations with AbbVie, Gilead, and Roche on accelerating the development and commercialization of XTX601.
Related topics